共 235 条
[1]
Adler RA(2016)Bisphosphonates and atypical femoral fractures Curr Opin Endocrinol Diabetes Obes 23 430-434
[2]
Adler RA(2018)Management of endocrine disease: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy Eur J Endocrinol 178 R81-R87
[3]
Andersen TF(1999)The Danish National Hospital Register. A valuable source of data for modern health sciences Dan Med Bull 46 263-268
[4]
Madsen M(2006)Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis N Engl J Med 355 2048-2050
[5]
Jørgensen J(2014)Denosumab and atypical femoral fractures Acta Orthop 85 1-1
[6]
Mellemkjoer L(2010)Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur N Engl J Med 362 1761-1771
[7]
Olsen JH(2007)Risk of subsequent fracture after low-trauma fracture in men and women J Am Med Assoc 297 387-394
[8]
Armamento-Villareal R(2013)Epidemiology of fracture risk with advancing age Journals Gerontol Ser A Biol Sci Med Sci 68 1236-1242
[9]
Napoli N(2016)Nonenzymatic glycation and degree of mineralization are higher in bone from fractured patients with type 1 diabetes mellitus J Bone Miner Res 31 190-195
[10]
Panwar V(2012)Incidence and demography of femur fractures with and without atypical features J Bone Miner Res 27 977-986